**Standing Order for Dispensing and Administration of COVID-19 Vaccine: 2025-2026**

**Procedure**

1) Assess for Need of Vaccination.

2) Screen for Contraindications and Precautions.

Contraindications:

· A severe allergic reaction (e.g., anaphylaxis) after a previous dose of the COVID-19 vaccine or to a component of the COVID-19 vaccine

Precautions:

· A diagnosed non-severe allergy to a component of the COVID-19 vaccine.

· Non-severe, immediate (onset less than 4 hours) allergic reaction after administration. of a previous dose of one COVID-19 vaccine type, if receiving the same vaccine type.

· Myocarditis or pericarditis within 3 weeks after a dose of any COVID-19 vaccine.

· Moderate to severe acute illness, with or without fever.

3) Provide Vaccine Information Statements.

4) Prepare to Administer Vaccine.

· Verify that the label on the vaccine states 2025-2026 Formula.

· Choose the needle gauge, needle length, and injection site.

5) Administer COVID-19 Vaccine

**For intramuscular administration**

* MNEXSPIKE (COVID-19 Vaccine, mRNA) injectable suspension, 2025-2026 Formula

Dispense single 0.2 mL dose for:

* + Individuals 12 years of age and older
  + For individuals previously vaccinated with any COVID-19 vaccine, administer the dose of MNEXSPIKE at least 3 months after the last dose of COVID-19 vaccine

Directions for use: Administer MNEXSPIKE as a single 0.2 mL dose

**OR**

* SPIKEVAX (COVID-19 Vaccine, mRNA) injectable suspension, 2025-2026 Formula
  1. Individuals 5 years of age through 11 years of age

Dispense single 0.25 mL dose, irrespective of COVID-19 vaccination status.

* For individuals previously vaccinated with any COVID-19 vaccine, administer the dose ≥ 2 months after the last dose of COVID-19 vaccine

Direction for use: Administer SPIKEVAX 0.25 mL dose

**OR**

* 1. Individuals 12 years of age and older

Dispense single 0.5 mL dose, irrespective of COVID-19 vaccination status.

* For individuals previously vaccinated with any COVID-19 vaccine, administer the dose ≥ 2months after the last dose of COVID-19 vaccine

Direction for use: Administer SPIKEVAX 0.5 mL dose

**OR**

* COMIRNATY (COVID-19 Vaccine, mRNA) injectable suspension, 2025-2026 Formula
  1. Individuals 5 years of age through 11 years of age

Dispense single 0.3 mL dose supplied in vials with blue caps and labeled with blue borders

* For individuals previously vaccinated with any COVID-19 vaccine, administer the dose at least 2 months after the last dose of COVID-19 vaccine

Directions for use: Administer COMIRNATY as a single 0.3 mL dose

**OR**

* 1. Individuals 12 years of age and older

Dispense single 0.3 mL dose supplied in prefilled syringes labeled with gray borders

* For individuals previously vaccinated with any COVID-19 vaccine, administer the dose at least 2 months after the last dose of COVID-19 vaccine

Direction for use: Administer COMIRNATY as a single 0.3 mL dose

**OR**

* NUVAXOVID (COVID-19 Vaccine, Adjuvanted) injectable suspension, 2025-2026 Formula

Dispense single 0.5 mL dose for:

* + Individuals 12 years of age and older
  + For individuals previously vaccinated with any COVID-19 vaccine, administer the dose of NUVAXOVID at least 2 months after the last dose of COVID-19 vaccine

Directions for use: Administer NUVAXOVID as a single 0.5 mL dose

6) Document the Vaccination.

7) Be Prepared to Manage Medical Emergencies.

8) Report Adverse Events to the Vaccine Adverse Event Reporting System (VAERS).

**Physician’s Signature**

**Date**

**Physician’s Name and MA License No.** (print legibly)